[1]
Bottomley P.A, Edelstein W., Foster T. et al.: In vivo solvent-suppressed
localized hydrogen nuclear magnetic resonance spectroscopy: A window
to metabolism? Proc. Nadl. Acad. Sci USA, 1985: 82, 2148–2152.
[2]
Kaibara T., Tyson R., Sutherland G. et al.: Human cerebral neoplasms
studied using MR spectroscopy: a review. Biochem. Cell. Biol., 1998: 76,
477–486.
[3]
Mader L., Roser W., Hagberg G., Scheider M.: Proton Chemical Shift
Imaging, metabolic maps, and single voxel spectroscopy of glial tumors.
MAGMA 1996: 4, 139–150.
[4]
Uysal E., Erturk M., Yildirim H. et al.: Multivoxel magnetic resonance
spectroscopy in gliomatosis cerebri. Acta Radiol., 2005: 46(6), 621–
624.
[5]
Demaerel P.: In vivo localized single-voxel proton magnetic resonance
spectroscopy of intracranial tumors. Int. J. Neuroradiol., 1997: 3, 94–
100.
[6]
Usenius J., Kauppinen R., Yainio P. et al.: Quantitative metabolite patterns of human brain tumors: Detection by 1H NMR spectroscopy in vivo
and in vitro. J. Comp. Assist. Tomogr., 1994: 18, 707–713.
[7]
Kubas B., Tarasów E., Dzienis W. et al.: Magnetic resonance proton
spectroscopy in neurooncology – preliminary report. Neurol. Neurochir.
Pol., 2001: Suppl 5, 90–100.
[8]
Prost R., Haughton V., Li S-Jiang: Brain Tumors: Localized H-1 MR Spectroscopy at 0,5 T. Radiology 1997: 204, 235238.
[9]
Stadlbauer A., Gruber S., Nimsky C. et al.: Preoperative grading of
gliomas by using metabolite quantification with high-spatial-resolution
proton MR spectroscopic imaging. , 2006: 238(3), 958–969.
[10]
Kułak W., Sobaniec W.: Magnetic resonance imaging of the cerebellum
and brain stem in children with cerebral palsy.Adv. Med. Sci., 2007: 52
(Suppl. 1), 180–182.
[11]
Kułak W., Sobaniec W., Kubas B. et al.: Spastic cerebral palsy: clinical magnetic resonance imaging correlation of 129 children. J. Child.
Neurol., 2007: 22(1), 8–14.
[12]
Kułak W., Sobaniec W., Sołowiej E., Boćkowski L.: Somatosensory and
visual evoked potentials in children with cerebral palsy: correlations and
discrepancies with MRI findings and clinical picture. Pediatr. Rehabil.,
2006: 9(3), 201–209.
[13]
Kulak W., Sobaniec W., Smigielska-Kuzia J. et al.: Metabolite profile
in the basal ganglia of children with cerebral palsy: a proton magnetic
resonance spectroscopy study. Dev. Med. Child. Neurol., 2006: 48(4),
285–289.
[14]
Lichy M.P., Plathow C., Schulz-Ertner D. et al.: Follow-up gliomas after
radiotherapy: 1H MR spectroscopic imaging for increasing diagnostic
accuracy. Neuroradiology, 2005: 47(11), 826–834.
[15]
Lazareff J., Bockhorst K., Curran J.: Pediatric Low-grade Gliomas: Prognosis with Proton Magnetic Resonane Spectroscopic Imaging. Neurosurg., 1998: 43(4), 809–817.
[16]
Galanaud D., Nicoli F., Chinot O. et al.: Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magn. Reson. Med., 2006: 55(6), 1236–1245.
[17]
Panigrahy A., Krieger M.D., Gonzalez-Gomez I. et al.: Quantitative short
echo time 1H-MR spectroscopy of untreated pediatric brain tumors:
preoperative diagnosis and characterization. AJNR Am. J. Neuroradiol.,
2006: 27(3), 60–72.
[18]
Likavcanová K., Dobrota D., Liptaj T. et al.: In vitro study of astrocytic
tumour metabolism by proton magnetic resonance spectroscopy. Gen.
Physiol. Biophys., 2005: 24(3), 327–335.
[19]
Guzmán-de-Villoria J.A., Sánchez-González J., Muńoz L. et al: 1
HMR
spectroscopy in the assessment of gliomatosis cerebri. AJR Am. J.
Roentgenol., 2007: 188(3), 710–714.
[20]
Bowen B.C.: Glial Neoplasms without Elevated Choline-Creatine Ratios.
Am. J. Neuroradiol., 2003: 24, 782–784.
[21]
Remy C., Fouilhe N., Barba L., Sam-Lai E.: Evidence that mobile lipids
detected in rat brain glioma by 1
H nuclear magnetic resonance correspond to lipid droplets. Cancer Res., 1997: 57, 407–414.
[22]
Tien R., Lai P., Smith J., Lazeyras F.: Single-voxel proton brain spectroscopy exam(PROBE/SY) in patients with primary brain tumors. AJR,
1996: 167, 201–209.
[23]
Moreno-Torres A., Martinez-Perez I., Baquero M. et al.: Taurine Detection by Proton Magnetic Resonance Spectroscopy in Medulloblastoma:
Contribution to Noninvasive Differential Diagnosis with Cerebellar Astrocytomas. Neurosurg, Baltimore 2004: 55(4), 824–829.
[24]
Kim J.H., Chang K.H., Na D.G. et al.: 3T 1
HMR spectroscopy in grading
of cerebral gliomas: comparison of short and intermediate echo time
sequences. AJNR Am. J. Neuroradiol., 2006: 27(7), 1412–1418.
[25]
Black P.: Management of malignant glioma: role of surgery in relation to
multimodality theraphy. J. Neurovirol., 1998: 4, 227–236.
[26]
Laws E., Shaffrey M.: The inherent invasiveness of cerebral gliomas:
implications for clinical management. Int. J. Dev. Neurosci, 1999: 17,
413–420.
[27]
. Walecki J., Tarasów E., Kubas B.: Hydrogen – 1
MR spectroscopy of the
peritumoral zone in patients with cerebral glioma: assessment of the
value of the method. Acad. Radiol., 2003: 10(2), 145–153.
[28]
Kimura T., Ohkubo M., Igarashi H. et al.: Increase in glutamate as a sensitive indicator of extracellular matrix integrity in peritumoral edema: a
3.0-tesla proton magnetic resonance spectroscopy study. J. Neurosurg.,
2007: 106(4), 609–613.
[29]
Magalhaes A., Godfrey W., Shen Y. et al.: Proton magnetic resonance
spectroscopy of brain tumors correlated with pathology. Acad Radiol.,
2005: 12(1), 51–57.
[30]
Morales H., Kwock L., Castillo M.: Magnetic resonance imaging and
spectroscopy of pilomyxoid astrocytomas: case reports and comparison
with pilocytic astrocytomas. J. Comput. Assist. Tomogr., 2007: 31(5),
682–687.
[31]
Chernov M.F., Hayashi M., Izawa M. et al.: Proton magnetic resonance
spectroscopy (MRS) of metastatic brain tumors: variations of metabolic
profile. Int. J. Clin. Oncol., 2006 Oct: 11(5), 375–384.
Scholar Google
PubMed